Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2019 /
Comment: Nivolumab plus ipilimumab combination for advanced NSCLC

27th Sep - 1st Oct 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 28.09.19
Views: 590

Dr Marina Garassino - National Tumor Institute, Milan, Italy

Dr Marina Garassino comments on data from the CheckMate-227 trial during a press conference at the 2019 ESMO congress.

This was a trial looking at the two immunotherapy drug combination of nivolumab plus ipilimumab as treatment for a subset of patients with advanced non-small cell lung cancer (NSCLC) compared to chemotherapy.

Watch the press conference here.

Watch Dr Marina Garassino's interview with ecancer here

Read more about the study here.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation